Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme

被引:187
作者
Helseth, R. [2 ]
Helseth, E. [3 ,4 ]
Johannesen, T. B. [5 ]
Langberg, C. W. [6 ]
Lote, K. [7 ]
Ronning, P. [4 ]
Scheie, D. [8 ]
Vik, A. [2 ,9 ]
Meling, T. R. [1 ]
机构
[1] Oslo Univ Hosp, Rikshosp, Dept Neurosurg, N-0027 Oslo, Norway
[2] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway
[3] Univ Oslo, Fac Med, Oslo, Norway
[4] Oslo Univ Hosp, Dept Neurosurg, Ulleval, Norway
[5] Norwegian Canc Registry, Oslo, Norway
[6] Oslo Univ Hosp, Dept Neurooncol, Ulleval, Norway
[7] Oslo Univ Hosp, Rikshosp, Dept Neurooncol, Oslo, Norway
[8] Oslo Univ Hosp, Rikshosp, Div Pathol, Oslo, Norway
[9] St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway
来源
ACTA NEUROLOGICA SCANDINAVICA | 2010年 / 122卷 / 03期
关键词
glioblastoma; survival; primary treatment; repeated surgery; prognostic factors; NEWLY-DIAGNOSED GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; MALIGNANT GLIOMA; PHASE-III; LONG-TERM; RADIOTHERAPY; RECURRENT; OUTCOMES; THERAPY; COMBINATION;
D O I
10.1111/j.1600-0404.2010.01350.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Objectives - To study overall survival (OS), prognostic factors, and repeated surgery in glioblastoma multiforme (GBM). Material and methods- Retrospective study of 516 consecutive adult patients who underwent primary surgery for a GBM in year 2003-2008. Results - Median age at primary surgery was 63.7 years (range 18.0-88.0). Median OS was 9.9 months. Age > 60 years, poor preoperative ECOG score, bilateral tumor, biopsy rather than resection, and no temozolomide chemoradiotherapy were negative risk factors. Repeat surgery was performed in 65 patients (13%). Median time between first and second surgery was 7 months. Indications for second surgery were increasing neurological deficits (35.4%), raised ICP (33.8%), asymptomatic but reoperated because of tumor progression verified on MRI (20.0%), and epileptic seizures (11%). Patients who underwent repeated surgery had longer OS; 18.4 months vs 8.6 months (P < 0.001). Conclusions - OS for adult GBM patients was 9.9 months. Negative prognostic factors were increasing age, poor neurological function, bilateral tumor involvement, biopsy instead of resection, and RT alone compared to temozolomide chemoradiotherapy. Our rate of repeated surgery for GBM was 13% and the main indications for second surgery were raised ICP and increasing neurological deficits. In a carefully selected group of patients, repeat surgery significantly prolongs OS.
引用
收藏
页码:159 / 167
页数:9
相关论文
共 31 条
[1]
'Recurrent' glioblastoma multiforme, when should we reoperate? [J].
Barbagallo, Giuseppe M. V. ;
Jenkinson, Michael D. ;
Brodbelt, Andrew R. .
BRITISH JOURNAL OF NEUROSURGERY, 2008, 22 (03) :452-455
[2]
Radiation response and survival time in patients with glioblastoma multiforme [J].
Barker, FG ;
Prados, MD ;
Chang, SM ;
Gutin, PH ;
Lamborn, KR ;
Larson, DA ;
Malec, MK ;
McDermott, MW ;
Sneed, PK ;
Wara, WM ;
Wilson, CB .
JOURNAL OF NEUROSURGERY, 1996, 84 (03) :442-448
[3]
Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma [J].
Barnholtz-Sloan, Jill S. ;
Williams, Vonetta L. ;
Maldonado, John L. ;
Shahani, Dilip ;
Stockwell, Heather G. ;
Chamberlain, Marc ;
Sloan, Andrew E. .
JOURNAL OF NEUROSURGERY, 2008, 108 (04) :642-648
[4]
Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project [J].
Chang, SM ;
Parney, IF ;
McDermott, M ;
Barker, FG ;
Schmidt, MH ;
Huang, W ;
Laws, ER ;
Lillehei, KO ;
Bernstein, M ;
Brem, H ;
Sloan, AE ;
Berger, M .
JOURNAL OF NEUROSURGERY, 2003, 98 (06) :1175-1181
[5]
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].
Esteller, M ;
Garcia-Foncillas, J ;
Andion, E ;
Goodman, SN ;
Hidalgo, OF ;
Vanaclocha, V ;
Baylin, SB ;
Herman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354
[6]
FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO
[7]
2-S
[8]
Treatment options for recurrent glioblastoma: pitfalls and future trends [J].
Franceschi, Enrico ;
Tosoni, Alicia ;
Bartolini, Stefania ;
Mazzocchi, Valeria ;
Fioravanti, Antonio ;
Brandes, Alba A. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (05) :613-619
[9]
MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[10]
Kleihues P, 2007, WHO CLASSIFICATION T, P72